Monday, July 14, 2025

Creating liberating content

Access Denied You don’t have permission to access ” on

Elon musk and the xAI logo. Vincent Feuray | Afp

Not commonly used, Vitamin D injections send the nutrient directly

Related News

Access Denied You don’t have permission to access ” on this server. Reference #18.2ef63717.1752482548.176df6 Source link

Elon musk and the xAI logo. Vincent Feuray | Afp | Getty Images Elon Musk on Monday said he does not support a merger between xAI and Tesla, as questions

Olympic bronze medalist and former world no. 1 badminton player Saina Nehwal has confirmed her separation from her husband and fellow shuttler Parupalli Kashyap after their seven-year-long marriage. The news

Not commonly used, Vitamin D injections send the nutrient directly to the bloodstream. Doctors provide these injections to patients, either on a monthly basis or as required. The most suitable

The WPI inflation had registered at 0.39 per cent in May, whilst it stood at 3.43 per cent in June last year. (AI image) India’s Wholesale Price Index (WPI) inflation

Gibran raises $2.6 million to build nature-inspired, adaptive AI systems (Representative AI image) BENGALURU: AI research startup Gibran has raised $2.6 million in a seed round led by Together Fund

Trending News

Access Denied You don’t have permission to access ” on this server. Reference #18.2ef63717.1752482548.176df6 Source link

Top stocks to buy (AI image) Stock market recommendations: According to Motilal Oswal Financial Services Ltd, the top stock picks for the week (starting July 14, 2025) are Suzlon, and

Bitcoin surged past the $120,000 mark for the first time on Monday, setting a new record as optimism grows over potential regulatory clarity in the US.Bitcoin reached a new all-time

Market experts indicate that ongoing uncertainty in trade talks could maintain markets in a consolidative phase. (AI image) Stock market today: Nifty50 and BSE Sensex, the Indian equity benchmark indices,

NEW DELHI: In an event-heavy week, stock investors will track quarterly earnings of several bluechip firms, likely outcome of ongoing India-US trade talks, and inflation data for market cues, analysts

NEW DELHI: Drug major Cipla is preparing to foray into the weight management segment in India, its MD and global CEO Umang Vohra said in the company’s annual report for

Top stocks to buy today: Stock recommendations for March 12, 2025

Word Count: 647 | Estimated Reading Time: 4 minutes


Top stocks to buy today: Stock recommendations for March 12, 2025
Top stocks to buy (AI image)

Stock market recommendations: According to Mehul Kothari, DVP – Technical Research, Anand Rathi Shares and Stock Brokers, Tube Investments, Godrej Agrovet Ltd, and Astrazeneca Pharma are the top stock picks for today:
TUBEINVEST: BUY Near ₹2850 | Stop Loss: ₹2600 | Target: ₹3350
The stock was highly oversold but has started to outperform in the last few days. Most importantly, a change of trend has been confirmed on the short-term charts. Today, a breakout was observed with strong volumes, reinforcing the strength of this move.
Previously, a breakdown occurred around ₹3200–₹3300, and the stock now appears to be preparing for a retest of that zone.
Thus, traders are advised to buy TUBEINVEST in the range of ₹2750–₹2850, with a stop-loss at ₹2600 on a closing basis, for an upside target of ₹3350 in the coming 1–3 months.
GODREJAGRO: BUY ABOVE ₹750 | Stop Loss: ₹700 | Target: ₹850
The stock has significantly outperformed the broader markets and has been consolidating in a range for the past 5–6 months. Based on the current structure, a breakout from this range appears imminent.
With limited downside risk from current levels, traders are advised to buy GODREJAGRO ABOVE ₹750, with a strict stop-loss at ₹700 on a closing basis, for an upside target of ₹850 in the coming 1–3 months.
ASTRAZEN: BUY Near ₹7800 | Stop Loss: ₹7500 | Target: ₹8400
The stock exhibits a structure similar to GODREJAGRO, but even stronger. Today, it delivered a major range breakout, and that too near its lifetime high.
Additionally, RSI has confirmed a breakout, and ADX (14) crossing 28 signals a strengthening trend, indicating the potential for a sharp upside move.
Thus, traders are advised to buy ASTRAZEN in the range of ₹7750–₹7850, with a stop-loss at ₹7500 on a closing basis, for an upside target of ₹8400 in the coming 1–3 months.
Disclaimer: The opinions, analyses and recommendations expressed herein are those of brokerage and do not reflect the views of The Times of India. Always consult with a qualified investment advisor or financial planner before making any investment decisions.





Source link

Most Popular Articles

Sign In

Welcome ! Log into Your Account